Avani R Pradeep1, Kaushik Patnaik1, Kanika Nagpal1, Shruti Karvekar1, Bhaskar L Ramamurthy2,3, Savitha B Naik4, Deepak Suke1, Priyanka Singh5, Arjun Raju6. 1. Department of Periodontics, Government Dental College and Research Institute, Bangalore, Karnataka, India. 2. Oxford Dental College and Hospital, Bangalore, Karnataka, India. 3. Azamgarh Dental College, Azamgarh, Uttar Pradesh, India. 4. Department of Conservative Dentistry and Endodontics Government Dental College and Research Institute, Bangalore, Karnataka, India. 5. Department of Ophthalmology, Grant Medical College and J.J Group of Hospitals, Mumbai, Maharashtra, India. 6. Department of Radio-Diagnosis, Uttarakhand Government Medical College, Haldwani, Uttarakhand, India.
Abstract
OBJECTIVE:Metformin (MF), used for the treatment of type 2 diabetes mellitus, has shown to possess properties favoring osteoblastic proliferation. The present study was designed to investigate the effectiveness of MF 1% gel as an adjunct to scaling and root planing in the treatment of intrabony defects in patients with chronic periodontitis. METHODS: The study comprised 65 individuals divided into two groups: 1% MF with SRP and placebo gel with SRP. Clinical parameters were evaluated at baseline, 3 months, and 6 months; they included plaque index, modified sulcus bleeding index, probing depth (PD), and clinical attachment level (CAL). Intrabony defect depth (IBD) was evaluated at the end of 6 months using computer-aided software. RESULTS: The mean PD reduction, CAL gain, and IBD depth reduction were found to be greater in the MF group than in the placebo group at all visits. The percentage of defect depth reduction was significantly greater in the MF group (26.8 ± 5.52%) than in the placebo sites (4.79 ± 2.30%, P < 0.001). CONCLUSION: One percent MF was found to significantly improve clinical and radiographic parameters in intrabony defects in patients with chronic periodontitis.
RCT Entities:
OBJECTIVE:Metformin (MF), used for the treatment of type 2 diabetes mellitus, has shown to possess properties favoring osteoblastic proliferation. The present study was designed to investigate the effectiveness of MF 1% gel as an adjunct to scaling and root planing in the treatment of intrabony defects in patients with chronic periodontitis. METHODS: The study comprised 65 individuals divided into two groups: 1% MF with SRP and placebo gel with SRP. Clinical parameters were evaluated at baseline, 3 months, and 6 months; they included plaque index, modified sulcus bleeding index, probing depth (PD), and clinical attachment level (CAL). Intrabony defect depth (IBD) was evaluated at the end of 6 months using computer-aided software. RESULTS: The mean PD reduction, CAL gain, and IBD depth reduction were found to be greater in the MF group than in the placebo group at all visits. The percentage of defect depth reduction was significantly greater in the MF group (26.8 ± 5.52%) than in the placebo sites (4.79 ± 2.30%, P < 0.001). CONCLUSION: One percent MF was found to significantly improve clinical and radiographic parameters in intrabony defects in patients with chronic periodontitis.
Authors: Ping Wang; Tao Ma; Dong Guo; Kevin Hu; Yan Shu; Hockin H K Xu; Abraham Schneider Journal: J Tissue Eng Regen Med Date: 2017-08-11 Impact factor: 3.963
Authors: Lucy Y Tao; Katarzyna B Łagosz-Ćwik; Jolanda M A Hogervorst; Ton Schoenmaker; Aleksander M Grabiec; Tim Forouzanfar; Fridus A van der Weijden; Teun J de Vries Journal: Front Cell Dev Biol Date: 2022-01-13